Biosimilars
34 results
Applied filters
Preparing to use ustekinumab biosimilar
16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing eculizumab biosimilar
6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for eculizumab biosimilars
6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use eculizumab biosimilar
6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing tocilizumab biosimilar
5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for tocilizumab biosimilar
5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
5 March 2024Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Good governance when implementing natalizumab biosimilar
6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.